Related Experiment Video
Updated: Aug 14, 2026
09:11
Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
Hormone replacement therapy and coronary artery disease
1Department of Medicine, M9.05 Royal Victoria Hospital, Montreal, Quebec, Canada.
Current Opinion in Obstetrics & Gynecology
|June 1, 1996
Summary
Estrogen therapy significantly reduces coronary artery disease in postmenopausal women by impacting all stages of atherosclerosis. Lipid metabolism improvements are noted, supporting hormone replacement therapy for cardiovascular risk reduction.
Area of Science:
- Cardiovascular Science
- Endocrinology
- Women's Health
Background:
- Postmenopausal estrogen therapy is linked to lower coronary artery disease (CAD) rates.
- Mechanisms of estrogen's cardioprotective effects are under active investigation.
Purpose of the Study:
- To explore how estrogen replacement therapy (ERT) influences the development and progression of cardiovascular disease.
- To confirm the impact of ERT on lipid metabolism in postmenopausal women.
Main Methods:
- Review of recent findings on estrogen's effects on atherogenesis, plaque formation, and vascular responsiveness.
- Analysis of studies investigating lipid metabolic alterations associated with ERT.
Main Results:
- Estrogen replacement appears to modify multiple stages of cardiovascular disease, including atherogenesis and plaque progression.
- Estrogen therapy positively alters lipid metabolism, an effect not diminished by progestin co-administration.
Conclusions:
- Estrogen therapy offers protection against cardiovascular disease in postmenopausal women.
- High cardiovascular disease risk should be an indication for postmenopausal hormone replacement therapy.
More Related Videos
Related Concept Videos
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...